IDEAYA Biosciences Submits IND Application for IDE892 Targeting MTAP-Deletion Solid Tumors

IDEAYA Biosciences has submitted an Investigational New Drug (IND) application for IDE892, a PRMT5 inhibitor aimed at treating MTAP-deletion solid tumors. The company plans to initiate dosing of the first patient in a Phase 1 dose escalation trial during the fourth quarter of 2025. IDE892 is being developed as a potential best-in-class therapeutic option for this specific genetic subset of cancers.

The preclinical profile of IDE892, along with its combination rationale with IDE397—IDEAYA’s proprietary MAT2A inhibitor—will be presented at the company’s 10-Year Anniversary R&D Day on September 8, 2025. This combination approach leverages mechanistic synergies between the two compounds and represents a key area of focus in IDEAYA’s oncology pipeline.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 3, 2025

Author

Mark Chiang